Hypertrophic and Keloid Scar Treatment Market Report 2025

The hypertrophic and keloid scar treatment market size has grown rapidly in recent years. It will grow from $7.72 billion in 2024 to $8.51 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to the rising incidence of hypertrophic and keloid scars, advancements in scar assessment, widespread adoption of topical treatments, surgical and invasive procedures, and patient demand for scar improvement.

The hypertrophic and keloid scar treatment market size is expected to see rapid growth in the next few years. It will grow to $12.51 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to emerging minimally invasive interventions, advancements in scar revision techniques, growing interest in combination therapies, increasing awareness and early intervention, and global aesthetic trends. Major trends in the forecast period include emerging injectable therapies, combination therapies for synergistic effects, patient-centric approaches, scar assessment technologies, and telemedicine for follow-up and consultations.

The hypertrophic and keloid scar treatment market is anticipated to witness growth due to an increase in the number of road accidents and burn cases. Road accidents involving at least one vehicle and individuals necessitate attention and effective treatment to address resulting scars. Hypertrophic and keloid scar treatments play a crucial role in lowering the height and tightness of scars, contributing to the market's expansion. For instance, statistics from the National Highway Traffic Safety Administration in August 2022 revealed a nearly 7% increase in motor vehicle traffic accident fatalities during the first three months of 2022 compared to the same period in 2021, highlighting the need for scar treatments in such cases.

The increasing popularity of aesthetic procedures is anticipated to drive growth in the hypertrophic and keloid scar treatment market in the future. Aesthetic procedures refer to non-invasive or minimally invasive cosmetic treatments aimed at enhancing an individual's appearance and addressing various cosmetic concerns. Treatments for hypertrophic and keloid scars are integral to these procedures, as they help reduce and improve the appearance of raised scars, resulting in a smoother and more visually appealing outcome. For example, in June 2024, The International Society of Aesthetic Plastic Surgery (ISAPS), a US-based organization for plastic surgeons, reported that in 2023, liposuction remained the most common surgical procedure, with over 2.2 million procedures performed, sustaining its lead from 2022. Breast augmentation and eyelid surgery closely followed, both showing notable growth. Specifically, eyelid surgery saw a remarkable 24% increase, reaching more than 1.7 million procedures, while rhinoplasty rose by 21.6%, totaling 1.1 million procedures compared to the previous year. Thus, the rise in aesthetic procedures is propelling the hypertrophic and keloid scar treatment market.

Leading companies in the hypertrophic and keloid scar treatment market are strategically focusing on the development of clinically proven solutions, particularly those based on silicone, such as medical-grade silicone strips. These therapeutic products made from high-quality silicone are formulated to promote scar healing and reduction, offering an effective solution for various scar types. An example is Scar Erase, a UK-based company, which launched clinically tested silicone strips designed for scar healing and reduction, catering to hypertrophic, keloid, post-surgery, and stretch mark scars.

Major players in the market are also investing in advanced dermatological lines that leverage innovative technologies such as Microcyn technology. This technology accelerates wound healing, combats infections, and alleviates symptoms, providing clinically proven solutions. Sonoma Pharmaceuticals, a US-based pharmaceutical company, introduced a line of office dispensed products, including Regenacyn Plus, which is clinically proven to enhance the appearance of keloid and hypertrophic scars, offering relief from itch and pain while reducing infection risk.

In July 2022, Sinclair Pharma, a UK-based aesthetics company, completed the acquisition of Viora Ltd. The financial details of the acquisition remain undisclosed. This strategic move is expected to grant Sinclair access to Viora’s portfolio of non-invasive and minimally invasive aesthetic devices. Additionally, the acquisition is anticipated to facilitate Sinclair's entry into the US market on a commercial scale. Viora Ltd., based in the US, specializes in providing medical aesthetic devices and solutions, including offerings related to scar and stretch mark revision, acne clearance, and various other aesthetic treatments.

Major companies operating in the hypertrophic and keloid scar treatment market include Smith & Nephew plc, Merz Pharmaceutical LLC, Lumenis Ltd., Enaltus LLC, Sonoma Pharmaceuticals Inc., Molnlycke Health Care AB, Suneva Medical Inc., Pacific World Corporation, Perrigo Company plc, Cynosure Inc., Alliance Pharma plc, Newmedical Technology Inc., HRA Pharma, Scar Heal Inc., McKesson Medical Surgical Inc., Johnson & Johnson Private Limited, Medtronic plc, 3M Company, Sinclair Pharma plc, Avita Medical, Stratpharma AG, Revitol Corporation Inc., Scarfade, Biodermis, Mederma, Silagen.

North America was the largest region in the hypertrophic and keloid scar treatment market in 2024. Asia-pacific is expected to be the fastest-growing region in the global hypertrophic and keloid scar treatment market report during the forecast period. The regions covered in the hypertrophic and keloid scar treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hypertrophic and keloid scar treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Hypertrophic and keloid scar treatment involves addressing scars that either remain within the boundaries of the original wound (hypertrophic) or extend beyond those boundaries and do not regress (keloids). Hypertrophic scars are contained within the area of the initial injury, while keloids spread outside the boundaries of the initial damage.

The main treatments for hypertrophic and keloid scars include cryotherapy, surgical excision, pressure dressings, intralesional 5-fluorouracil, superficial X-ray, intralesional corticosteroid injection, and others. Cryotherapy is a medical procedure that uses extremely cold liquid or a cryoprobe to freeze and destroy abnormal tissue. It is employed to destroy the core of keloid scars while preserving surface-level cells and tissues. Various products, including topical products, laser products, injectables, and others, are used during treatment. The end-users of hypertrophic and keloid scar treatment include hospitals, clinics, and other healthcare facilities.

The hypertrophic and keloid scar treatment market research report is one of a series of new reports that provides hypertrophic and keloid scar treatment market statistics, including hypertrophic and keloid scar treatment industry global market size, regional shares, competitors with a hypertrophic and keloid scar treatment market share, detailed hypertrophic and keloid scar treatment market segments, market trends and opportunities, and any further data you may need to thrive in the hypertrophic and keloid scar treatment industry. This hypertrophic and keloid scar treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hypertrophic and keloid scar treatment market consist of revenues earned by entities by providing occlusive dressings, compression therapy, intralesional corticosteroid injections, cryosurgery, excision, radiation therapy, laser therapy, interferon (IFN) therapy, doxorubicin, bleomycin, and verapamil. The market value includes the value of related goods sold by the service provider or included within the service offering. The hypertrophic and keloid scar treatment market also includes sales of skin camouflage, silicon gels, and skin needling. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.